Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
Articolo
Data di Pubblicazione:
2017
Citazione:
Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating? / G. Zuccotti, V. Fabiano. - In: THE ITALIAN JOURNAL OF PEDIATRICS. - ISSN 1824-7288. - 43:(2017), pp. 17.1-17.2. [10.1186/s13052-017-0341-4]
Abstract:
Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29 wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation patients. On the contrary, immunoprophylaxis is not recommended in preterm babies born between 29 and 35 wGA. We evaluated the impact of RSV-related healthcare expenditures in infants in the first 3 years of life in Italy, Lombardy Region. In light of the collected data and considering the cost of a complete palivizumab prophylaxis, extending it to babies 29-32 wGA, aged less than 6 months, appears to be a cost-effective strategy.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Palivizumab; Respiratory syncytial virus; Prophilaxys; Preterm
Elenco autori:
G. Zuccotti, V. Fabiano
Link alla scheda completa:
Link al Full Text: